IP Library Patent Application 18062265
Patent Application
App. No. 18/062,265

Compositions and Methods for Treating Cancer

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/062,265
Abstract

Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.

Claims (20)

1 . A method of targeting one or more Myeloid-Derived Suppressor Cells (MDSCs) comprising contacting a subject or subject sample with a glycan-interacting antibody, wherein the subject or subject sample includes at least one MDSC.

2 . The method of claim 1 , wherein the glycan-interacting antibody binds to STn.

3 - 9 . (canceled)

10 . A method of treating a subject comprising administering an anti-STn antibody to the subject, wherein the subject has at least one tumor comprising an MDSC.

11 - 12 . (canceled)

13 . The method of claim 10 , wherein the anti-STn antibody is an IgG antibody.

14 . The method of claim 10 , wherein the anti-STn antibody comprises an antibody-drug conjugate (ADC).

15 . The method of claim 14 , wherein the ADC comprises at least one conjugate selected from one or more of an auristatin, a maytansine, a tubulysin, a vinca alkaloid, a pyrrolobenzodiazepine dimer, a camptothecin, a duocarmycin, an amanitin, a phosphoinositide 3-kinase (PI3K) inhibitor, and a mitogen-activated protein kinase kinase (MEK) inhibitor.

16 . The method of claim 15 , wherein the ADC comprises one or more polymer, wherein the one or more polymer connects the anti-STn antibody and the at least one conjugate.

17 . The method of claim 16 , wherein the one or more polymer comprises one or more of a poly(ethylene glycol) (PEG), a poly(N-(2-hydroxypropyl)methacrylamide) (polyHPMA), a poly(α-amino acid), a carbohydrate polymer, a glycopolysaccharide, a glycolipid, a glycoconjugate, a polyglycerol, a polyvinyl alcohol, a poly(acrylic acid), a polyketal, and a polyacetal.

18 . The method of claim 17 , wherein the one or more polymer comprises a poly(1-hydroxymethylethylene hydroxymethylformal) (PHF).

19 - 23 . (canceled)

24 . A method of identifying a candidate for anti-STn antibody treatment, the method comprising:

a. obtaining a sample from a subject;

b. identifying one or more MDSC in the sample; and

c. evaluating the one or more MDSC for STn expression using an anti-STn antibody.

25 . The method of claim 24 , wherein the sample is a tumor sample.

26 . The method of claim 24 , wherein the sample is a fluid sample.

27 . The method of claim 26 , wherein the fluid sample is selected from blood, plasma, lymph, saliva, and interstitial fluid.

28 - 42 . (canceled)

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2023
From: PRENDERGAST, JILLIAN M.; EAVARONE, DAVID A.; RAO, PATRICIA
To: SIAMAB THERAPEUTICS, INC.
Reel/Frame 062598/0570 →
CHANGE OF NAME Recorded Feb 6, 2023
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 062598/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2023
From: SIAMAB THERAPEUTICS, INC.
To: SEATTLE GENETICS, INC.
Reel/Frame 062598/0605 →